Using this report, dealmakers will effectively and efficiently determine the suitablility of Allergan as a prospective partner, their business development objectives, interests and recent partnering activity, key partnering contacts, and partnering contract documents signed with their recent partners.
The report provides a firm basis for initial due diligence into Allergan as a prospective partner company.
The initial chapters of this report provide an orientation of bigpharma’s dealmaking and business activities.
Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2008 pharmaceutical revenues. Chapter 3 analyses the most active dealmakers between 2005 and 2009 in M&A and partnering deals announced, whilst chapter 4 identifies the top deals of 2005 to 2009 according to reported deal size.
Chapter 5 provides details on how to approach bigpharma companies with partnering opportunities whilst chapter 6 lists forthcoming partnering events and conferences where bigpharma companies will be present to discuss opportunities face to face.
Chapter 7 provides a series of matrices that summarize the company’s activity in terms of marketed and pipeline products, partnering interests and partnering activity by therapeutic area.
The main body of the report is provided in chapter 8. An in-depth profile of the company provides everything required to assess the suitability of a company as a prospective partner. This includes a company overview, detailed analysis of the company’s marketed and pipeline disease targets, partnering interests, partnering activity according to deal type, phase of development, therapy area. The profile also includes in-depth contact information for individuals within the business development function.
The company profile is also provided with a comprehensive listing of contract documents available in the public domain. The listing is sorted by deal type – therefore co-promotion deals are listed separately to licensing, M&A and supply deals, and so on.
Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
In summary, the report provides the user with the tools to make successful contact with the right bigpharma partners effectively and efficiently.
Key benefits
Partnering Agreements with Allergan 2010 report provides the user with the following key benefits
Detailed company profile of the company
In-depth marketed and pipeline product activity for the company
Partnering interests and therapy focus revealed
Partnering activity since 2000 – number of deals per year
Partnering activity for 2005-2009
Activity by deal type
Activity by phase of development
Activity by therapeutic area
List of recent partner companies
Comprehensive access to actual contracts entered into by the company and its partners
Insight into the terms included in a partnering agreement
Understand the key deal terms the company has agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Report scope
Partnering Agreements with Allergan 2010 is intended to provide the reader with an in-depth understanding of the partnering activities and interests of the company, enabling the effective assessment and selection of partners of choice, based on the latest knowledge of a company’s approach to partnering.
Partnering Agreements with Allergan 2010 includes
Detailed company profile including
Full contact details
Business developer contact details including name, title, email and telephone (where available)
Marketed indications
Pipeline indications
Partnering interests and indications
Partnering activity since 2000
Current partner companies since 2005
Partnering activity since 2005 by
Deal type
Stage of development
Therapy area
Numerous charts showing the dealmaking activity of the company since 2005
The tools to enable effective and efficient preparation for partnering negotiation with the company
Listing of contract documents between the company and its partners
The leading M&A and partnering deals by value 2005-2009
Most active M&A and partnering dealmakers 2005-2009
Chapter 1 – Introduction
Chapter 2 – Bigpharma – The Top 50
Chapter 3 – Most active bigpharma dealmakers
3.1 Bigpharma M&A activity
3.2 Bigpharma partnering
Chapter 4 – Top bigpharma deals by value
4.1 Bigpharma M&A
4.2 Bigpharma partnering
Chapter 5 – Submitting Opportunities to Bigpharma such as Allergan
5.1 How to submit an opportunity
5.2 Opportunity submission template
5.3 Sending emails
5.4 Face to face at partnering events
5.5 Online submission forms
Chapter 6 – Forthcoming bigpharma partnering events
6.1 Forthcoming events
Chapter 7 – Allergan – therapy locator
7.1 How to use the therapy matrix tables
7.2 Therapeutic area definitions
7.3 Allergan – Therapeutic target matrix – marketed and pipeline compounds
7.5 Allergan – Therapeutic target matrix – expressed partnering interests
7.6 Allergan – Therapeutic target matrix – recent deals – 2005-2009
Chapter 8 – Bigpharma Company Profiles – Allergan
8.1 How to use company profiles
8.2 Field definitions
8.3 Allergan company profile
Company contact details
Subsidiary companies
Primary therapy areas
Business development contacts
Company description
Marketed therapeutic indications
Pipeline (phase I-III) therapeutic indications
Partnering interests
Partnering interests - therapeutic indications
Partnering frequency per annum - 2000-2009
Current partner companies (2005-2009)
Recent deals 2005-2009
By deal type
By stage of development
By therapy area
Contract documents - link direct to each document
Figures in report
Figure 1: Bigpharma – top 50 by pharma sales
Figure 2: Leading Bigpharma M&A companies, 2005-2009
Figure 3: Bigpharma M&A activity – top 50 by pharma sales
Figure 4: Leading Bigpharma partnering companies, 2005-2009
Figure 5: Bigpharma partnering activity – top 50 by pharma sales
Figure 6: Leading M&A deals involving bigpharma by value, 2005-2009
Figure 7: Leading partnering deals by value, 2005-2009
Figure 8: Typical partnering opportunity submission template
Figure 9: Therapeutic area definitions
Figure 10: Therapeutic target matrix – marketed and pipeline compounds
Figure 11: Therapeutic target matrix – expressed partnering interests
Figure 12: Therapeutic target matrix – recent deals 2005-2009
Figure 13: Company profile template and definitions used in report
Figure 14: Allergan – Dealmaking frequency 2000-2009
Figure 15: Allergan - recent deals (2005-2009) by deal type
Figure 16: Allergan - recent deals (2005 – 2009) by stage of development
Figure 17: Allergan – recent deals (2005 – 2009) by therapy area
Figure 18: Recent Allergan partnering deals (2003-2009) where contract document available
Figure 19: Online partnering resources
Other selected research from the 'Business Development' category:
Bigpharma Agreements Handbook 2007
Oncology Market Leaders - Analyses and Outlook - 2010-2025
Other selected research from the 'Licensing' category:
Partnering Agreements with Hospira 2010
This report provides all the information you require to better understand Hospira Labs and its partnering interests and activities over the past five years. Learn More
Bigpharma Agreements Handbook 2007
Other selected research from the 'Pharma Partnering Guides' category:
Partnering Agreements with Merck & Co 2010
This report provides all the information you require to better understand Merck & Co Labs and its partnering interests and activities over the past five years. Learn More
Partnering Agreements with Pfizer 2010
This report provides all the information you require to better understand Pfizer Labs and its partnering interests and activities over the past five years. Learn More
Other selected research from the 'Companies' category:
Partnering Agreements with Eli Lilly 2010
This report provides all the information you require to better understand Eli Lilly Labs and its partnering interests and activities over the past five years. Learn More
Partnering Agreements with Genentech 2010
This report provides all the information you require to better understand Genentech Labs and its partnering interests and activities over the past five years. Learn More